Some leaders begin their careers in strategy.
Gisele began hers on the manufacturing floor.
Fresh out of graduate school with a Master’s degree in Biomedical Engineering, she made a deliberate decision to become a Field Automation and Validation Engineer. While many aspiring leaders sought faster paths into management, Gisele wanted something different. She wanted to understand pharmaceutical manufacturing where quality is truly created—next to the equipment, alongside operators, and closest to the patient.
“I wanted to learn the business from the ground up,” she explains. “Being on the manufacturing floor taught me that every decision matters. It taught me urgency, accountability, and how to make informed decisions even when you don’t yet have perfect information.”
That decision became the foundation of a career spanning more than two decades across manufacturing, automation, computer system validation, regulatory compliance, quality systems, laboratory informatics, digital manufacturing, enterprise transformation, mergers and acquisitions, and today, Quality Control digitization.
Few leaders have experienced the pharmaceutical value chain as comprehensively as Gisele. Having worked across organizations including Baxter, Pfizer, Amgen, Schering-Plough, Wyeth, PDL Biopharma, and GSK, she has developed a unique perspective that bridges manufacturing, quality, technology, and business strategy.
Every role added another perspective.
Every challenge reinforced the same belief.
Quality isn’t simply a department. It’s the way an organization thinks.
Building Quality Beyond Compliance
One of the defining experiences of Gisele’s career came during the Consent Decree period at Schering-Plough.
For many professionals, it was an intense period of regulatory remediation.
For Gisele, it became an education in leadership.
She learned that organizations don’t build quality systems to pass inspections.
They build them to protect patients.
That lesson fundamentally changed how she viewed compliance.
Today, she challenges organizations to rethink quality—not as a regulatory obligation or organizational gatekeeper—but as a strategic capability that enables innovation, strengthens trust, improves operational excellence, and ultimately delivers better outcomes for patients.
She says, “Compliance should never be viewed as the finish line, it’s a culture that should be embedded into everything we do.”
Connecting Manufacturing, Quality, and Digital Intelligence
Today, as Director of Internal Manufacturing Operations Quality (IMOQ) QC Digitization at Pfizer, Gisele is helping shape the next evolution of pharmaceutical manufacturing.
While many organizations focus on digitizing paper processes, she believes digitization should fundamentally change how decisions are made.
She explains, “Technology isn’t the destination; better decisions are.”
Her vision extends beyond automation.
She sees a future where data, artificial intelligence, advanced analytics, and manufacturing operate as one connected ecosystem.
One idea she is particularly passionate about challenges in decades of traditional Quality Control practices.
For years, manufacturers have followed the same model: produce the batch, collect samples, send them to the laboratory, wait for results, and then decide whether production can continue.
Gisele believes the future looks very different.
“The future isn’t about moving samples to the laboratory; it’s about moving laboratory intelligence to the manufacturing line,” says Giesel.
As technologies such as Process Analytical Technology (PAT), advanced sensors, automation, spectroscopy, and artificial intelligence continue to mature, she envisions Quality Control becoming increasingly integrated directly into manufacturing operations.
Instead of discovering issues after production, manufacturers will predict, prevent, and continuously verify quality throughout the manufacturing process.
“My vision is that one day we won’t be asking whether a batch passed quality testing—we’ll already know, because quality will have been continuously verified throughout the manufacturing process.”
For Gisele, this represents far more than technological progress.
It represents a completely new operating model for pharmaceutical manufacturing.
Transformation Happens at the Speed of Trust
Although technology often receives the spotlight, Gisele believes successful transformation has very little to do with software.
“It’s about people.”
Throughout her career leading global initiatives—including enterprise LIMS deployments, enterprise Quality Management Systems, QualityDocs, and the digital integration of more than 120 legacy quality systems following Pfizer’s acquisition of Seagen—she discovered a simple truth.
People rarely resist change.
They resist uncertainty.
That’s why she invests heavily in communication, transparency, and involving teams early in the transformation journey.
Her leadership philosophy is built on trust, psychological safety, humility, and continuous learning.
She intentionally hires for mindset before skill.
Technical expertise can be developed.
Character cannot.
“I look for curiosity, resilience, integrity, humility, accountability, and people who genuinely love learning,” she says.
Because innovation isn’t created by individual brilliance.
It emerges when diverse teams challenge one another respectfully, build on each other’s ideas, and pursue a common purpose.
As a certified NeuroLeadership Institute trainer and executive mentor, Gisele believes one of a leader’s greatest responsibilities is creating environments where people feel safe enough to ask questions, challenge assumptions, and continue growing.
She asserts, “The most innovative organizations aren’t the ones that avoid mistakes, they’re the ones that learn the fastest.”
A Legacy of Significance
Behind every technology initiative and every transformation program lies a much deeper purpose.
For Gisele, that purpose has always been patients.
Every quality improvement.
Every simplified process.
Every digital capability.
Every innovation.
Ultimately contributes to delivering safe medicines to families she may never meet.
But perhaps her greatest source of inspiration came long before her professional career.
Growing up, she watched both her grandfather and her mother lead through significant change with resilience, humility, integrity, and service. Later, mentors and executive coaches continued shaping her leadership philosophy.
One conversation has stayed with her throughout her career.
After thanking one of her coaches and asking how she could ever repay everything he had invested in her, his answer was remarkably simple:
“Don’t pay me back. Build other leaders.”
She has carried that advice ever since.
Today, mentoring emerging leaders, coaching teams, speaking at conferences, and helping others discover their potential have become some of the most rewarding aspects of her career.
Because, in her words,
“Leadership isn’t measured by how many people report to you. It’s measured by how many leaders you help create.”
The Future Starts With Us
When asked what legacy she hopes to leave behind, Gisele doesn’t talk about technology.
Technology will continue to evolve.
Platforms will eventually be replaced.
Artificial intelligence will become more powerful.
But people—and the impact we have on them—endure.
She reflects,“If people remember me, I hope it isn’t because of the systems I implemented. I hope it’s because I helped organizations think differently about quality, empowered teams to embrace change with confidence, and developed leaders who continued creating meaningful change long after I was gone.”
She pauses before offering one final thought to the next generation of leaders.
“Don’t build your career by chasing titles.
Build it by seeking experiences.
Learn manufacturing.
Learn quality.
Learn technology.
Most importantly, learn people.
The future belongs to leaders who can connect disciplines, build trust, and inspire others to achieve more than they ever thought possible.”
Because, ultimately…
True leadership isn’t measured by the systems we build. It’s measured by the leaders we leave behind and the significance of the change they continue to create.
A Call to Action
As our industry embraces AI, automation, and the next generation of digital manufacturing, the question is no longer whether we will transform—it’s how we will lead that transformation.
Will we simply digitize today’s processes?
Or will we reimagine what’s possible?
The future of pharmaceutical manufacturing will not be defined by technology alone. It will be defined by leaders who have the courage to challenge conventional thinking, invest in people, and build organizations where quality, innovation, and purpose work together.
The future of quality is not something we wait for. It’s something we create—together.
